.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE16_Ensitrelvir.Ensitrelvir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE16_Ensitrelvir.Ensitrelvir| name: | Ensitrelvir |
| ATC code: | J05AE16 | route: | oral |
| n-compartments | 2 |
Ensitrelvir is an oral antiviral drug that acts as a SARS-CoV-2 3CL protease inhibitor. It is approved in Japan for the treatment of COVID-19 in adult and pediatric patients. The drug is used to shorten the duration of symptoms and reduce viral replication in patients infected with COVID-19.
Pharmacokinetic parameters reported for healthy adult Japanese male participants. Single oral dose, fasted state.
Ishibashi, T, et al., & Kubota, R (2024). Population Pharmacokinetics of Ensitrelvir in Healthy Participants and Participants with SARS-CoV-2 Infection in the SCORPIO-SR Study. Clinical pharmacokinetics 63(12) 1723–1734. DOI:10.1007/s40262-024-01446-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39565561
Shimizu, R, et al., & Kubota, R (2023). A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations. Clinical drug investigation 43(10) 785–797. DOI:10.1007/s40261-023-01309-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/37798608
Westberg, M, et al., & Lin, MZ (2024). An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Science translational medicine 16(738) eadi0979–None. DOI:10.1126/scitranslmed.adi0979 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38478629